Key clinical point: Bortezomib appears to overcome the resistance seen in patients with Waldenström macroglobulinemia with CXCR4 mutations.
Major finding: Progression-free and overall survival were not significantly different between WM patients with CXCR4 mutations and those with CXCR4 wild type (log-rank, P = .994 and P = .407, respectively).
Study details: An analysis of 43 WM patients treated with bortezomib/rituximab and genotyped to determine CXCR4 mutation status.
Disclosures: The study was supported by the National Institutes of Health, the Leukemia and Lymphoma Society, and the International Waldenström Macroglobulinemia Foundation. One of the authors reported consulting and research funding from Takeda, which markets bortezomib, and other companies.
Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241.
This Week's Must Reads
'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4
Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7
Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661
FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781
Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6
Must Reads in Indolent Lymphoma
Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31
Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241
Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018